Evaluation value of CD8+ T lymphocyte level in immunotherapy efficacy in patients with advanced hepatocellular carcinoma

Abstract

Abstract: Objective To evaluate the efficacy of CD8⁺ T lymphocytes in immunotherapy in patients with advanced hepatocellular carcinoma.Methods A total of 89 patients with advanced hepatocellular carcinoma admitted to the hospital from March 2019 to July 2022 were selected. All patients received immunotherapy. According to clinical efficacy, patients were divided into effective group (partial response (PR) and complete response (CR)) and ineffective group (disease progression (PD) and stable disease (SD)). The level of CD8⁺ T lymphocytes in the 2 groups and the clinical data in the 2 groups were compared. The influencing factors of immunotherapy ineffectiveness in patients with advanced hepatocellular carcinoma was analyzed. The predictive value of CD8⁺ T lymphocytes in patients with advanced hepatocellular carcinoma was analyzed. Results After treatment, SD, PD, PR and CR of the 89 patients were 8, 24, 57 and 0, respectively. The objective response rate (ORR) was 64.04% (57/89), with 32 cases in the ineffective group and 57 cases in the effective group The level of CD8⁺ T lymphocytes in effective group was higher than that in ineffective group (P<0.05). The ECOG score > 0, Child-Pugh classification was B grade, Barcelona stage (BCLC) was end-stage, poorly differentiated, extrahepatic metastasis, and alpha-fetoprotein (AFP) ≥20 ng/mL of proportion of cases in effective group was higher than that in the effective group (P<0.05). Child-Pugh grade B, end-stage BCLC, and AFP and CD8⁺ T lymphocyte levels were influential factors for immunotherapy efficacy in patients with advanced hepatocellular carcinoma (P<0.05). Receiver operating characteristic curve (ROC) curve showed that the area under curve (AUC) value of CD8⁺ T lymphocyte level in predicting immune response in advanced hepatocellular carcinoma patients was 0.781 (P<0.05). Conclusion CD8⁺ T lymphocyte level can be used to predict the efficacy of immunotherapy in patients with advanced hepatocellular carcinoma, and low CD8⁺ T lymphocyte level of patients have a greater risk of treatment failure.

Key words: CD8⁺ T lymphocytes, Late, Hepatocellular carcinoma, Immunotherapy, Clinical effect, Predictive value

ZHANG Xiang, LI Ying-ying, TANG Qing, LI Wei, SUN Li-zhu. Evaluation value of CD8⁺ T lymphocyte level in immunotherapy efficacy in patients with advanced hepatocellular carcinoma[J]. Chinese Hepatolgy, 2023, 28(9): 1084-1087.

References

[1] Lee TK, Guan XY, Ma S. Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications. Nat Rev Gastroenterol Hepatol,2022,19(1):26-44.
[2] Tran NH, Munoz S, Thompson S, et al. Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF/TKI and immunotherapy. Hepatology,2022,76(4):1203-1218.
[3] Patil NS, Nabet BY, Muller S, et al. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell,2022,40(3):289-300.
[4] Geng Y, Zhang Q, Feng S, et al. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Cancer Med,2021,10(4):1222-1239.
[5] Sendi H, Yazdimamaghani M, Hu M, et al. Nanoparticle Delivery of miR-122 Inhibits Colorectal Cancer Liver Metastasis. Cancer Res, 2022,82(1):105-113.
[6] 吴侃, 徐晓, 张敏娜, 等. CD8⁺T淋巴细胞联合治疗线数对晚期肺癌免疫治疗疗效的预测价值. 浙江临床医学,2021,23(3):320-323.
[7] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版). 中华肝脏病杂志,2022,30(4):367-388.
[8] Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol,2017,18(3):143-152.
[9] Yang C, Zhang H, Zhang L, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol,2023,20(4):203-222.
[10] Guo S, Wang X, Zhou H, et al. PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity. Biomolecules,2022,12(9):1226.
[11] Kudo M. Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass. Liver Cancer,2022,11(3):185-191.
[12] Hakozaki T, Richard C, Okuma Y, et al. Gutmicrobiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated withanti-PD-1/P D-LI antibody-based immunotherapy. J Clin Oncol,2020,38(15):3095.
[13] Wen W, Zhang Y, Zhang H, et al. Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol,2023,149(3):969-978.
[14] Chui NN, Cheu JW, Yuen VW, et al. Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1. Hepatol Commun,2022,6(1):178-193.
[15] 孙小虎, 王璐, 白静慧, 等. 晚期肝癌免疫微环境CD38表达水平与PD-1抑制剂疗效相关性分析. 肝脏,2023,28(1):75-78,94.
[16] 曹银彪, 李俊锋, 唐浩文, 等. 血清甲胎蛋白作为BCLC C期肝细胞癌免疫联合靶向序贯外科治疗预后标志物的临床研究. 中华肝胆外科杂志,2023,29(1):22-27.
[17] Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science,2018,359(6371):97-103.
[18] Tang K, Seo J, Tiu BC, et al. Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy. JAMA Dermatol,2022,158(2):189-193.
[19] Chen L, Jiang YZ, Wu SY, et al. Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial. Clin Cancer Res,2022,28(13):2807-2817.
[20] Qian Y, Su H, Ge Y, et al. Prognostic value of PD-L1 expression combined with hypoxia-associated immunosuppression in hepatocellular carcinoma. Biomark Med,2022,16(6):435-448.

Evaluation value of CD8⁺ T lymphocyte level in immunotherapy efficacy in patients with advanced hepatocellular carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	WANG Kai-li, HU Xiao-wei, YIN Jian, LIU Qing-yang, WANG Qiu-bo. Diagnosis and evaluation of serum midkine levels in response to TACE treatment in patients with hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(9): 1072-1074.
[2]	GE Shu, LIU Yang-yang. Contrast-enhanced ultrasonography and enhanced CT in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(9): 1075-1078.
[3]	XI Liang, QUAN Xing-pu, WANG Xiao-wei, WANG Yun, QIU He, XU Jun-wang. Efficacy of endoscopic titanium clip combined with cyanoacrylate injection in the treatment of gastric varices [J]. Chinese Hepatolgy, 2023, 28(8): 912-915.
[4]	NIE Bin, ZHAO Tie-jun, ZHANG Sheng-long. A prognostic analysis on the radical resection of primary hepatocellular carcinoma with microvascular invasion by different resection margin schemes [J]. Chinese Hepatolgy, 2023, 28(8): 921-923.
[5]	HU Zhi-qiang, MEN Fen-yong, LIU Dong. A correlation analysis between immune-related adverse events and the curative effect caused by immune checkpoint inhibitors on patients with advanced primary Hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(8): 935-937.
[6]	XU Jia-pin, SHAO Chun-yan, LIU Di-fa, XU Ya-chun. The value of diffusion weighted imaging of voxel incoherent motion in predicting microvascular invasion and evaluating the efficacy of TACE therapy on hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(8): 938-942.
[7]	YUAN Qing-gong, ZHANG Yan, LI Jun-hui, YANG Wen-bin. Effect of fibronectin type III domain containing 5 on the metastatic activity of HepG2 hepatoma cells in vitro and its mechanism [J]. Chinese Hepatolgy, 2023, 28(8): 943-946.
[8]	CHEN Li-xia, SHEN Li-lei, ZHENG Yi. Retrospective study of red blood cell distribution width-platelet ratio in evaluating the severity of liver fibrosis in patients with autoimmune hepatitis [J]. Chinese Hepatolgy, 2023, 28(8): 957-960.
[9]	HUANG Qian, LI Ya-nan, ZENG Da-wu. Expression and prognostic value of ANLN, CYP2C9 and HMMR in hepatitis B virus-associated hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(7): 775-780.
[10]	LI Gang, CAO Zhi-qun, NIU Shuai. Effect of TACE on serum tumor markers and recurrence risk after radical hepatocellular carcinoma resection at different time [J]. Chinese Hepatolgy, 2023, 28(7): 781-784.
[11]	CHEN Yong-ying, PENG Pan, XU Lei-lei. Application of SVM prediction model in judging the degree of pathological differentiation of primary hliver cancerepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(7): 785-788.
[12]	YANG Ya-meng, LUO Dan-feng. The inhibitory effects of mTOR inhibitor combined with ursodeoxycholic acid on the growth, immune escape, and Ras/ERK signaling pathway of hepatocellular carcinoma in rats [J]. Chinese Hepatolgy, 2023, 28(7): 789-793.
[13]	ZHUANG Xiao-lei, ZOU Hong-rui, HOU Jing-yue. Predictive value of serum IL-15, pro-ADM and MDH1 for bacterial infection in patients with cirrhosis combined with upper gastrointestinal bleeding [J]. Chinese Hepatolgy, 2023, 28(6): 654-659.
[14]	GUO Dan-dan, QIN Ling, GAO Weng-feng, YUAN Chun-wang, ZHANG Ying-hua, ZHANG Yong-hong. Correlation between the plasma levels of interleukin-33 and hepatocellular carcinoma, thermal ablation therapy [J]. Chinese Hepatolgy, 2023, 28(6): 665-667.
[15]	MA Bo-heng, WANG Xia, WU Ying. An evaluation of serum biochemical indexes, pathological characteristics and surgical treatment efficacy of sarcomatoid hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(6): 676-679.